DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.
Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with...
AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more...
